Display options
Cite
Bacigalupo A, Sica S. HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide. Adv Hematol. 2016;2016:7802967doi: 10.1155/2016/7802967.
Bacigalupo, A., & Sica, S. (2016). HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide. Advances in hematology, 20167802967. https://doi.org/10.1155/2016/7802967
Bacigalupo, Andrea, and Sica, Simona. "HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide." Advances in hematology vol. 2016 (2016): 7802967. doi: https://doi.org/10.1155/2016/7802967
Bacigalupo A, Sica S. HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide. Adv Hematol. 2016;2016:7802967. doi: 10.1155/2016/7802967. Epub 2016 Apr 07. PMID: 27143973; PMCID: PMC4838781.
Copy Download .nbib Format: NLM
Share it on

Adv Hematol. 2016;2016:7802967. doi: 10.1155/2016/7802967. Epub 2016 Apr 07.

HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide.

Advances in hematology

Andrea Bacigalupo, Simona Sica

Affiliations

  1. Istituto di Ematologia, Universita' Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli, Rome, Italy.

PMID: 27143973 PMCID: PMC4838781 DOI: 10.1155/2016/7802967

Abstract

The use of high dose posttransplant cyclophosphamide (PT-CY) introduced by the Baltimore group approximately 10 years ago has been rapidly adopted worldwide and is becoming a standard for patients undergoing unmanipulated haploidentical (HAPLO) transplants. PT-CY has been used following nonmyeloablative as well as myeloablative conditioning regimens, for bone marrow or peripheral blood grafts, for patients with malignant and nonmalignant disorders. Retrospective comparisons of HAPLO grafts with conventional sibling and unrelated donor grafts have been published and suggest comparable outcome. The current questions to be answered include the use of PT-CY for sibling and unrelated donors transplant, possibly in the context of prospective randomized trial.

References

  1. Blood. 2006 Apr 15;107(8):3065-73 - PubMed
  2. Biol Blood Marrow Transplant. 2016 Jan;22(1):125-33 - PubMed
  3. Biol Blood Marrow Transplant. 2014 May;20(5):724-9 - PubMed
  4. Biol Blood Marrow Transplant. 2014 Oct;20(10):1573-9 - PubMed
  5. Blood. 2014 Jul 17;124(3):334-43 - PubMed
  6. J Clin Oncol. 2013 Apr 1;31(10):1310-6 - PubMed
  7. Biol Blood Marrow Transplant. 2015 Jul;21(7):1299-307 - PubMed
  8. Immunol Lett. 2013 Sep-Oct;155(1-2):21-3 - PubMed
  9. Blood. 2015 May 7;125(19):3024-31 - PubMed
  10. Biol Blood Marrow Transplant. 2014 Dec;20(12):1975-81 - PubMed
  11. Biol Blood Marrow Transplant. 2013 Jan;19(1):117-22 - PubMed
  12. Biol Blood Marrow Transplant. 2015 Aug;21(8):1506-14 - PubMed
  13. Blood. 2014 Oct 23;124(17):2735-43 - PubMed
  14. Blood. 2012 Nov 22;120(22):4285-91 - PubMed
  15. Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S37-9 - PubMed
  16. Bone Marrow Transplant. 2015 Apr;50(4):476-82 - PubMed
  17. Nature. 1966 Apr 9;210(5032):139-40 - PubMed
  18. Bone Marrow Transplant. 2005 Aug;36(4):349-54 - PubMed
  19. Blood. 1983 Feb;61(2):341-8 - PubMed
  20. Biol Blood Marrow Transplant. 2002;8(7):377-86 - PubMed
  21. Biol Blood Marrow Transplant. 2013 Apr;19(4):602-6 - PubMed
  22. Cancer. 2013 Mar 1;119(5):978-85 - PubMed
  23. Blood. 2015 Aug 20;126(8):1033-40 - PubMed
  24. Blood. 1994 Dec 1;84(11):3948-55 - PubMed
  25. Biol Blood Marrow Transplant. 2015 Apr;21(4):646-52 - PubMed

Publication Types